BRIEF-Ascendis Pharma, Novo Nordisk Sign Deal For Transcon Technology

-0.47%

-1.16%

-1.81%

Dow Jones Industrial Average

DJI

47885.97

-0.47%

S&P 500 index

SPX

6721.43

-1.16%

NASDAQ

IXIC

22693.32

-1.81%

Nov 4 (Reuters) - Ascendis Pharma A/S A71.F:

ASCENDIS PHARMA AND NOVO NORDISK SIGN COLLABORATION FOR DEVELOPMENT AND COMMERCIALIZATION OF TRANSCON TECHNOLOGY-BASED PRODUCTS IN METABOLIC AND CARDIOVASCULAR DISEASES
TO RECEIVE UP TO $285 MILLION IN PAYMENTS
TO RECEIVE UP TO $77.5 MILLION PER ADDITIONAL PRODUCT
NOVO NORDISK TO COVER EARLY DEVELOPMENT AND COMMERCIALIZATION COSTS

Source text: ID:nGNX96QTVd

Further company coverage: A71.F

(Gdansk Newsroom)

((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.